Chemoresistant tumor cell lines display altered epidermal growth factor receptor and HER3 signaling and enhanced sensitivity to gefitinib

2008 ◽  
Vol 123 (12) ◽  
pp. 2939-2949 ◽  
Author(s):  
Tiziana Servidei ◽  
Anna Riccardi ◽  
Simona Mozzetti ◽  
Cristiano Ferlini ◽  
Riccardo Riccardi
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tumor Cell ◽  
Cell Lines ◽  
Growth Factor Receptor ◽  
Tumor Cell Lines ◽  
Enhanced Sensitivity ◽  
Epidermal Growth

scholarly journals Mutations of the epidermal growth factor receptor gene in gastrointestinal tract tumor cell lines

2006 ◽  
Author(s):  
Toshimoto Kimura ◽  
Chihaya Maesawa ◽  
Kenichiro Ikeda ◽  
Go Wakabayashi ◽  
Tomoyuki Masuda
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Gastrointestinal Tract ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tumor Cell ◽  
Cell Lines ◽  
Receptor Gene ◽  
Growth Factor Receptor ◽  
Tumor Cell Lines ◽  
Epidermal Growth

scholarly journals Peptide–Au Cluster Probe: Precisely Detecting Epidermal Growth Factor Receptor of Three Tumor Cell Lines at a Single-Cell Level

ACS Omega ◽  
2017 ◽  
Vol 2 (1) ◽  
pp. 276-282 ◽  
Author(s):  
Jiao Zhai ◽  
Lina Zhao ◽  
Lingna Zheng ◽  
Fuping Gao ◽  
Liang Gao ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tumor Cell ◽  
Growth Factor Receptor ◽  
Single Cell Level ◽  
Tumor Cell Lines ◽  
Cell Level ◽  
Epidermal Growth ◽  
Au Cluster

Computational Evaluation and In Vitro Validation of New Epidermal Growth Factor Receptor Inhibitors

2020 ◽  
Vol 20 (18) ◽  
pp. 1628-1639
Author(s):  
Sergi Gómez-Ganau ◽  
Josefa Castillo ◽  
Andrés Cervantes ◽  
Jesus Vicente de Julián-Ortiz ◽  
Rafael Gozalbes
Keyword(s):  
Cell Proliferation ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Binding Affinity ◽  
Cell Lines ◽  
Growth Factor Receptor ◽  
Significant Activity ◽  
Epidermal Growth

Background: The Epidermal Growth Factor Receptor (EGFR) is a transmembrane protein that acts as a receptor of extracellular protein ligands of the epidermal growth factor (EGF/ErbB) family. It has been shown that EGFR is overexpressed by many tumours and correlates with poor prognosis. Therefore, EGFR can be considered as a very interesting therapeutic target for the treatment of a large variety of cancers such as lung, ovarian, endometrial, gastric, bladder and breast cancers, cervical adenocarcinoma, malignant melanoma and glioblastoma. Methods: We have followed a structure-based virtual screening (SBVS) procedure with a library composed of several commercial collections of chemicals (615,462 compounds in total) and the 3D structure of EGFR obtained from the Protein Data Bank (PDB code: 1M17). The docking results from this campaign were then ranked according to the theoretical binding affinity of these molecules to EGFR, and compared with the binding affinity of erlotinib, a well-known EGFR inhibitor. A total of 23 top-rated commercial compounds displaying potential binding affinities similar or even better than erlotinib were selected for experimental evaluation. In vitro assays in different cell lines were performed. A preliminary test was carried out with a simple and standard quick cell proliferation assay kit, and six compounds showed significant activity when compared to positive control. Then, viability and cell proliferation of these compounds were further tested using a protocol based on propidium iodide (PI) and flow cytometry in HCT116, Caco-2 and H358 cell lines. Results: The whole six compounds displayed good effects when compared with erlotinib at 30 μM. When reducing the concentration to 10μM, the activity of the 6 compounds depends on the cell line used: the six compounds showed inhibitory activity with HCT116, two compounds showed inhibition with Caco-2, and three compounds showed inhibitory effects with H358. At 2 μM, one compound showed inhibiting effects close to those from erlotinib. Conclusion: Therefore, these compounds could be considered as potential primary hits, acting as promising starting points to expand the therapeutic options against a wide range of cancers.

Epidermal growth factor receptor expression is associated with rapid tumor cell proliferation in renal cell carcinoma

1997 ◽  
Vol 28 (11) ◽  
pp. 1255-1259 ◽  
Author(s):  
Holger Mock ◽  
Guido Sauter ◽  
Niels Buchholz ◽  
Thomas C Gasser ◽  
Lukas Bubendorf ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tumor Cell ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Tumor Cell Proliferation ◽  
Epidermal Growth

Abstract 490: Different localization of epidermal growth factor receptor affects the response of Cetuximab in the irradiated NSCLC cell lines

2010 ◽  
Author(s):  
Seung-Hee Ryu ◽  
Youn-Joo Yang ◽  
Soo Young Moon ◽  
Jeong-Yoon Oh ◽  
Si Yeol Song ◽  
...  
Keyword(s):  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Cell Lines ◽  
Growth Factor Receptor ◽  
Nsclc Cell ◽  
Epidermal Growth
Sign in / Sign up

Export Citation Format

Share Document